Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non–small cell lung cancer

Cancer

Volumn 122, Issue 13, 2016, Pages 2091-2100

  Halasz, Lia M ^a   Uno, Hajime ^b   Hughes, Melissa ^b   D'Amico, Thomas ^c   Dexter, Elisabeth U ^d,e   Edge, Stephen B ^d,e   Hayman, James A ^f   Niland, Joyce C ^g   Otterson, Gregory A ^h   Pisters, Katherine M W ⁱ   Theriault, Richard ⁱ   Weeks, Jane C ^b   Punglia, Rinaa S ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c DUKE CANCER INSTITUTE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

breast neoplasms; comparative effectiveness research; neoplasm metastasis; non small cell lung carcinoma; radiosurgery

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STEREOTACTIC RADIOSURGERY; WHOLE BRAIN RADIATION THERAPY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; COMPARATIVE STUDY; LUNG NEOPLASMS; MULTICENTER STUDY; RADIOSURGERY; SECONDARY; SKULL IRRADIATION; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CRANIAL IRRADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPENSITY SCORE; RADIOSURGERY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84963959912     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30009     Document Type: Article

References (18)

1. Greenberg H, Chandler WF, Sandler HM. Brain tumors. New York: Oxford University Press, 1999.
2. Zimm S, Wampler GL, Stablein D, Hazra T, Young HF. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer. 1981;48:384-394.
3. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6:1-9.
4. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037-1044.
5. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-2491.
6. Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134-141.
7. Halasz LM, Weeks JC, Neville BA, Taback N, Punglia RS. Use of stereotactic radiosurgery for brain metastases from non–small cell lung cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;85:e109-e116.
8. Weeks J. Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network. Oncology (Williston Park). 1999;13:69-71.
9. Niland JC. NCCN outcomes research database: data collection via the Internet. Oncology (Williston Park). 2000;14:100-103.
10. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
11. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996;34:73-84.
12. Census 2000 Summary File 3—United States/prepared by the U.S. Census Bureau, 2002.
13. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
14. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54:948-963.
15. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655-661.
16. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
17. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665-1672.
18. Sahgal A, Aoyama H, Kocher M, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91:710-717.